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Summary
Purpose: Three previous mitomycin-cisplatin-based chemo-
therapy trials conducted within the EORTC Gynecological
Cancer Cooperative Group (GCCG) in patients with dissemi-
nated squamous-cell carcinoma of the uterine cervix (SCCUC)
suggested that with such regimens a higher overall response
rate and a higher complete response rate could be obtained
compared to what might have been expected from cisplatin
alone. In that respect the combination of bleomycin, vindesine
(Eldesine®), mitomycin C and cisplatin (BEMP) was the most
promising. In the present study BEMP has been compared
with the best single agent, cisplatin (P) in the expectation that
improved response rates might translate into a better survival.
Patients and methods: Eligible patients were those with
SCCUC and disseminated measurable disease outside previ-
ously irradiated areas, aged < 75 years, with a WHO perfor-
mance status =$2 and adequate bone marrow, renal, hepatic
and pulmonary function, who gave consent according to
regulations followed in individual institutions. Patients were
randomized to BEMP: E 3 mg/m2 day 1, P 50 mg/m2 day 1, B
15 mg (24-hour infusion) day 2-4 and M 8 mg/m2 (at alternate
cycles), or P 50 mg/m2. The first four cycles were given every 3
weeks (induction phase). Subsequent cycles were given every
four weeks (maintenance phase), during which B was deleted
from BEMP (MEP). Patients failing on P could be treated with
BEM. Of the 287 patients entered, 235 were eligible and 201
evaluable for response.
Results: BEMP induced a significantly higher response rate
than P (42% vs. 25%, P = 0.006). There was no difference in
complete response rate (11% vs. 7%). BEMP was significantly
more toxic than P (± BEM), both with respect to hematologic
and nonhematologic toxicities. After a median follow-up of 6.1
years, survival curves were not significantly different. Median
progression-free survival and overall survival were 5.3 and 10.1
months with BEMP and 4.5 and 9.3 months with P (± BEM).
respectively. In a multivariate analysis of prognostic factors for
survival, a lower age (P = 0.003), a lower performance status
(P = 0.0001) and a short (< 1 year) interval since diagnosis
(P = 0.0152) were all associated with an increased risk of dying.
For progression-free survival, lower age, prior radiotherapy,
locoregional involvement and no prior surgery were associated
with a high risk. Treatment with BEMP or P had no significant
impact on survival, but for progression-free survival there was
a trend in favor of BEMP (P - 0.0893). Adjusting for prognostic
factors did not change the effect of treatment.
Conclusions: Combination chemotherapy with BEMP
produces more toxicity and more responses compared with
cisplatin alone in patients with disseminated SCCUC. but this
does not translate into a better survival. Therefore, in the
palliative setting single-agent cisplatin should remain the
standard therapy for these patients.
Key words: cervix cancer, cisplatin combination chemotherapy,
single-agent cisplatin
Introduction
Traditionally, chemotherapy has been limited to a pallia-
tive role in those patients with distant metastatic disease
at presentation or recurrent disease following primary
local therapy for whom salvage procedures - irradiation
or pelvic exenteration - are inappropriate or have failed
[1]. Several reviews on the role of chemotherapy in this
setting have stressed the low single agent activity of
conventional agents and indicated response rates in the
range of 10% to 25% [2-6]. Cisplatin, even to-day, is
considered the single most active cytotoxic agent [7, 8].
Contrary to what has been observed with the other con-
ventional agents in the past, complete responses do occur,
although in a low percentage (± 10%). Studies performed
in the Gynecologic Oncology Group (GOG) in the US
elucidated that there is no clear clinical relevant superi-
ority of one dose or schedule of cisplatin [9, 10]. In a
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large randomized trial, comparing cisplatin doses of
50 mg/m2, 100 mg/m2 (both on a single day) and 20
mg/m2/day (for 5 consecutive days), all repeated every
21 days, overall response rates were 20.7%, 31.4% and
25.0%, and complete response rates were 10.0%, 12.7%
and 8.6%, respectively [9]. There was no significant
difference in response duration, progression-free inter-
val or survival. The study concluded that a single dose of
100 mg/m2 induced significantly more responses overall
than a single dose of 50 mg/m2, but this was not the
case for complete responses. The additional conclusion
was that, because of the increased toxicity with the
higher dose and the lack of clinical benefit the use of the
higher dose schedule was not justified. However, reaching
a complete response appeared to be of benefit, as the
survival in those patients was strikingly different from
those in all other response categories. Whether that was
a positive contribution of the drug itself or a selection
due to the treatment of patients who anyhow would do
better, was unclear.
Combination chemotherapy seems to increase the
response rate up to 40% or 50%, although large varia-
tions in that (range O%-93%) have been observed,
mostly reflecting differences in sample size, methods of
assessment of response and patient characteristics [1].
Again, as observed in the earlier mentioned large single
agent cisplatin trial, patients who obtain a complete
response seem to do better than those who do not. Three
studies performed within the EORTC Gynecological
Cancer Cooperative Group (GCCG) with several cis-
platin—mitomycin C based regimens all suggested not
only a higher overall response rate than usually seen
with cisplatin alone, but also a higher complete response
rate [11-13]. Some of the patients in complete response,
in particular those with only lung metastases, showed a
very long disease-free survival. This was in agreement
with literature data suggesting that some of these pa-
tients even may be cured by chemotherapy [14, 15].
These observations posed a dilemma, i.e., should all
patients be treated with cisplatin-based combination
chemotherapy in order to increase the number of com-
plete responses and, if not, is there a subgroup of
patients that might benefit from this approach? A retro-
spective analysis of studies using cisplatin alone and
those using cisplatin-containing combinations did not
suggest that with the latter form of treatment much more
complete responses could be obtained [1]. However, a
definitive conclusion on that could only be made by
performing a randomized phase III trial. We decided to
do this by comparing cisplatin alone with BEMP, which
consisted of a combination of bleomycin, vindesine,
mitomycin C and cisplatin, and seemed to be the most
efficacious regimen studied by the group at that time [12].
Patients and methods
Eligible patients included those women who had histologically con-
firmed advanced (stage IVB) or recurrent squamous-cell carcinoma of
the uterine cervix (SCCUC) not suitable for curative treatment with
surgery and/or radiotherapy. Patients had to have measurable lesions
at distant sites outside previously irradiated areas and had to give
informed consent. The latter had to be obtained according to the at
that time operative regulations followed in the individual participating
institutions.
Ineligible patients included those with malignancies of the cervix
other than SCCUC, age > 75. a life expectancy < 3 months, a WHO
performance status 3 or 4, prior chemotherapy, prior extensive radio-
therapy within 8 weeks, previous or concurrent cancer at other sites,
with the exception of adequately treated basal cell carcinoma of the skin,
a serum creatinine level > 1.5 mg/dl (or > 132 umol/1) and/or creatinine
clearance < 60 ml/min/1.73 m2. white blood cells (WBC) < 4000/mm3
and/or platelet count < IOO,OOO/mnr\ bilirubin > 1.5 mg/dl (or > 25.6
umol/1). severe pulmonary dysfunction (MBC <30 1/min. FEV,
< 1000 cc). neurologic conditions which could interfere with evalua-
tion of neurologic toxicity. or conditions of impaired mobility in which
neurologic toxicity might cause an unacceptable degree of incapacity,
bone lesions only detectable on bone scans, sclerotic bone metastases
and serous effusions as single tumor response parameters, signs or
symptoms of brain involvement or leplomeningeal disease, overt psy-
chosis or senility.
Patients were prospectively stratified by participating institution,
WHO performance status (0, 1 or 2), whether or not they had received
radiotherapy to the pelvis, whether they had only distant metastases or
loco-regionally recurrent disease also, and whether the distant metas-
tases were only in lung and/or lymph nodes or also at other distant
sites. Thereafter patients were randomized to receive BEMP or cisplatin
alone (P). The BEMP schedule was given as follows, vindesine
(Eldesine®) was given first at a dose of 3 mg/m2 intravenously (i.v.) on
day 1 (and repeated on day 8), followed by cisplatin 50 mg/m2 given i.v.
with appropriate hydration. Thereafter a continuous i.v. infusion of
bleomycin (15 mg/day) was given for three days (day 2-4) followed at
the end by an i.v. administration of mitomycin C 8 mg/m2. The latter
drug was to be given on alternate cycles (i.e., cycle I, 3, 5 etc.). In the P
arm cisplatin was given at the same dose as was given in the BEMP
arm. i.e. 50 mg/m2.
There were two phases in the treatment protocol; an induction
phase (the first four cycles) and a maintenance phase. During the
induction phase the regimens in both arms of the study were to be
given every three weeks, during the maintenance phase every four
weeks Patients were assessed for response after the first two cycles,
after the first four cycles, and every three months thereafter or sooner
if necessary.
If after the first two cycles there was progression of disease patients
in the BEMP arm went off study (and treatment was at the discretion
of the investigator), those in the P arm switched over to BEM (vinde-
sine 3 mg/m2. day 1 + 8; bleomycin 15 mg/day (day 1-3); mitomycin C
8 mg/m2, day 4: every four weeks). All other patients, i.e., those
responding or stable, continued for another two cycles of BEMP or P.
If after the first four cycles there was progression of disease patients
in the BEMP arm went off study, and again treatment was left to the
investigator. Patients in the P arm with progression at that time, but
also those who were stable at that time, were supposed to receive BEM.
Responders and stable disease patients in the BEMP then continued
treatment, but without bleomycin (MEP: vindesine 3 mg/m2. day I + 8;
mitomycin C 8 mg/m2, day I on alternate cycles; cisplatin 50 mg/m2.
day 1; every four weeks). Responding patients in the P arm continued
with cisplatin at four-weekly intervals.
Dose adjustments were specified for hematologic. neurologic,
hepatic, renal and pulmonary toxicity or dysfunction from other
causes. Toxicity was graded according to WHO criteria [16]. With
respect dose modification for myelosuppression. all modifications were
carried out referring to counts measured on day 1 (with the exception
of the vindesine dose on day 8 in the MEP regimen, where it is adjusted
according to the counts on the same day). If WBC are <2000/mm3
and/or platelets <50,000/mm3 on day 1 the schedule was postponed
for one week (maximum two weeks during the induction phase). If the
delay was more than two weeks during the induction phase the patient
went off study.
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All patients were planned to receive at least two cycles of chemo-
therapy unless there was rapidly progressive disease, such that further
treatment was not in the best interest of the patient. Patients in whom a
complete response was obtained either by BEMP or P continued treat-
ment for another six cycles from the moment complete response was
recorded. Thereafter treatment was stopped. Patients with partial
response continued treatment in both arms of the study until disease
progression became evident of excessive toxicity occurred. The same
was true for patients with stable disease in the BEMP arm. As
mentioned earlier, those with stable disease in the P arm after four
cycles were supposed to receive BEM as second-line treatment.
Complete response was defined as complete disappearance of all
clinically detectable tumor(s) together with a return of relevant blood
chemistries to normal values for at least four weeks. Partial response
was defined as a 50% or more decrease in total tumor size of the
lesions(s) which was measured or evaluated to determine the effect of
therapy by two observations not less than four weeks apart. This was
to be found in the absence of progression of any lesion or appearance
of a new lesion(s). Stable disease (or no change) was defined as a
change of less than 50% reduction or less than 25% increase in the
size of one or more measurable of evaluable lesions for the duration of
at least 12 weeks.
Statistical considerations
The main endpoint of the study was the response rate. The target
difference to observe was an increase from 25% (with cisplatin alone)
to 45% with BEMP. Based on the accrual in previous studies it was
expected that 140 patients (70 in each arm) could be accrued in less
than three years, allowing a 80% power for observing the difference if
it existed (with a = 0.05). Patients were to be followed until death to
allow for a comparison of survival. If the combination resulted in an
increase of at least 50% in the median survival the power for detecting
it would be near 80% (a = 0.05). For the comparison of toxicities the
Wilcoxon test and the chi squared test for trend were used. Survival
curves were constructed according to Kaplan-Meier and compared
with log-rank analysis or a test for linear trend, where appropriate. A
prognostic factor analysis was performed including the following
prognostic factors: treatment, age, performance status, prior radio-
therapy, extent of disease (i.e., only distant metastases or locoregional
involvement also), site of the metastases (only lung/lymph nodes or
also elsewhere), interval since diagnosis, FIGO stage, prior surgery,
initial blood counts (WBC and platelets). For this, first a univariate
analysis was performed to asses the individual prognostic value of all
variables; second, these variables were included in a Cox model with
the treatment indicator; third a Cox model was fit including all
variables and treatment; fourth, a backward selection procedure was
performed on a Cox model including all prognostic variables and
treatment. These analyses were performed for both survival and pro-
gression-free survival.
Results
From September 1986 to December 1991 251 patients
were enrolled. Based on an interim analysis, thereafter
the study was kept open only for patients with only lung
and/or lymph node metastases in order to allow for a
further analysis of that specific subgroup. However, only
36 patients were accrued in the additional years and the
study was closed in May 1996. Although 40 institutions
participated in this study, 70% of the enrolled patients
were derived from 12 institutions. Of the 287 enrolled
patients, 235 fulfilled the criteria of eligibility and 197
were fully evaluable (i.e., evaluable for both response
and toxicity), while an additional 26 were only partially
Table I. Patient and disease characteristics.
Number of eligible patients
Age (years)
Median
Range
WHO performance status
Median
Range
Prior treatment
Prior radiotherapy (unknown)
Prior surgery (unknown)
Prior chemotherapy (unknown)
Prior hormones (unknown)
Initial disease stage (FIGO)
I-IV
IVB(IVB without RT)
Unknown
Extent of disease
Distant metastases (DM) only
DM plus locoregional disease
Unknown
Site of metastases
Only lung and/or lymph node mets
Elsewhere
Unknown
Histologic cell type
Squamous
Other
Squamous cell type
Keratinizing
Large-cell non-keratinizing
Small-cell non-keratinizing
Unknown
BEMP
(H = 143)
119
53
25-72
1
0-2
101(3)
60(4)
3(3)
1(5)
113
17(16)
13
69
69
5
93
41
9
129
14
42
39
20
28
P
(;i = 144)
116
52
28-76
1
0-3
110(4)
68(2)
0(4)
0(4)
112
13(9)
19
68
71
5
93
43
8
136
8
49
40
18
29
evaluable (4 for response). Reasons for not being eligible
were; disease stage, extent or pathology (n = 25), meas-
urability (n = 12), performance status (n = 7), prior
therapy (n — 3), no data (n — 5). The characteristics of
all randomized patients are summarized in Table 1. The
median number of treatment cycles in the BEMP arm
was significantly lower than in the P (± BEM) arm: four
(range 0-16) versus six (range 0-17) (P = 0.0017). Of
note, only 45 patients in the P arm received BEM as
second-line treatment. Due to the increased toxicity expe-
rienced in the BEMP arm (see below), dose reductions
and dose delays occurred more frequently in the BEMP
than in the P arm. As result of this, the dose intensity of
cisplatin was different in the two arms, i.e., median 13.9
mg/m2/week (range 9.3-20.8 mg/nr/week) with BEMP
and 15.2 mg/m2/week (range 4.3-17.8 mg/m2/week) with
P(P = 0.0002). Graphically this is depicted in Figure 1.
Toxicity
There was more frequent and more severe hematologic
and nonhematologic toxicity observed in the BEMP arm
than in the P arm (Tables 2 and 3). This was not only the
case in the first two cycles, when all evaluable patients
indeed received BEMP or P, but also when all treatment
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Table 3 BEMP versus P - nonhematologic toxicity."
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Figure I. Dose intensity (mg/m2/week) during treatment with combi-
nation chemotherapy (BEMP) and during single-agent cisplatin (P).
Table 2 BEMP versus P - hematologic toxicity/
Time of Number of Median nadir value
assessment evaluable patients (x 1000/mm3)
WBC/platelets
WBC Platelets
First two cycles
BEMP
P
/'-value"
All cycles
BEMP
P - . BEM
P-value
48/46
40/39
0.0001
62/60
47/46
0.0001
" Worst nadir analysis
b
 Wilcoxon test.
2.2
4.7
0.0218
1.9
3.8
0.0063
197
245
160
208
cycles were taken into account, i.e., also patients who
received BEM after P. Table 2, summarizing the hema-
tologic toxicity, shows a worst nadir analysis, in which
counts on days 1,8, 15, and 22 were taken into account.
With respect to nonhematologic toxicity, several toxicities
did occur in a similar frequency in the two arms of the
study. These include: local toxicity at the site of the
infusion, nausea and vomiting, diarrhea, oral toxicity,
pulmonary toxicity, infection, cardiac toxicity, neuro-
pathy, consciousness, or changes in blood pressure.
However, this can be explained by the fact some patients
experienced additional toxicities when they received BEM
after P. Indeed, in the first two cycles infection, diarrhea,
stomatitis and neuropathy occurred significantly more
frequent with BEMP than with P (Table 3). Skin toxicity
occurred also more frequently in the BEMP arm
(P = 0.061). There were five early deaths in the BEMP
arm and two in the P arm. Two of these in each arm were
due to malignant disease. The others (all with BEMP)
included a sepsis with acute renal dysfunction, a case of
bleeding from the tumor, without thrombocytopenia or
evident tumor progression and one patient died of un-
known cause at home. Because of the reported dyspnea,
Type of
Alopecia
Drug fever
Diarrhea
Infection
Stomatitis
Neuropathy
Allergy
First two cycles
BEMP
80(33)
35(1)
29(2)
16(3)
13(2)
11(1)
2(0)
P
12(1)
5(0)
12(1)
2(0)
3(0)
3(0)
0(0)
/>-valueb
0.001
0.001
0.006
0.001
0.004
0.009
0.175
All cycles
BEMP
88(57)
40(1)
37(2)
19(5)
17(2)
33(5)
9(2)
P
45(22)
21(2)
21(2)
13(2)
14(1)
24(2)
0(0)
P-v-d\ueb
0.001
0.008
0.145
0.120
0.329
0.062
0.002
11
 In percentages, any grade (grade 3 and 4).
b
 x
2
-tesl for trend.
Table 4 Response rates and their 95% confidence intervals.
BEMP rate
(95% CI)
Prate
(95% CI)
P-value
All entered patients
Response rate
Complete response
All eligible patients
Response rate
Complete response
All evaluable patients
Response rate
Complete response
n = 143
35(27-43)
9(5-15)
n = 119
42(33-51)
11 (5-16)
H = 9 3
54 (43-64)
14(8-23)
/; = 144
20(14-27)
6(2-11)
n = 116
25(17-33)
7(3-13)
n = 108
27(18-35)
7(3-14)
0.005
0.250
0.006
0.279
0.001
0.129
toxicity of bleomycin or mitomycin C could have played
a role, but was uncertain. If only grade 3 and 4 toxicities
were taken together and the incidence was compared
between the two arms, then significant differences were
noticed in the first two cycles for both hematologic
toxicity (20 of 143 vs. 0 of 144, P = 0.001) and non-
hematologic toxicity (19 of 143 vs. 6 of 144, P = 0.006).
When all cycles were taken into account then only the
incidence of grade 3 and 4 hematologic toxicitiy re-
mained significantly more frequent with BEMP (33 of
143 vs. 6 of 144, P = 0.001), while grade 3 and 4 non-
hematologic toxicity occurred in a similar fashion. In
these analyses nausea, vomiting and alopecia were ex-
cluded.
Response and survival
BEMP induced significantly more responses than P.
However, no difference in complete response rate was
found. This observation was done irrespective of eligi-
bility status or evaluability status (Table 4). However, the
fact that no significant difference in complete response
rate was observed might simply have been a result of
insufficient numbers, because in fact complete response
rates doubled when only evaluable patients were taken
into account. Both for BEMP and for P it was evident
that complete response rates depended on the category
of patients explored. It was highest in the most favorable
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Table 5 Median survival and progression survival with 95% confidence
intervals (in months).
BEMP(95%CI) P(95%CI)
Survival
All entered patients 10.1(8.3-12.5) 9.3(8.1-11.2)
Only distant metastases 11.5(8.7-13.7) 10.1(8.0-11.7)
Only lung a/o lymph node mets 12.9(10.1-16.8) 11.3(9.5-16.5)
FIGO stage IVB 9.7(5.0-13.2) 10 3(8.1-16.2)
Progression-free survival
All entered patients 5.3 (4.0-7.0) 4.5 (4.0-5 0)
Only distant metastases 6.9 (4.7-7.0) 5.1 (3.6-6.2)
Only lung a/o lymph node mets 7.4(4.7-9.5) 5.9(4.0-7.1)
FIGO stage IVB 4 2(1.9-7.6) 4.1(3.2-6.2)
patient group, i.e. those with only lung and/or lymph
node metastases and no locoregional disease. In this
latter category 11 of 42 (26%) patients achieved a com-
plete response on BEMP versus 5 of 40 (13%) patients
on P (P = 0.118). Among the patients who responded,
this was first documented in the first cycle for 39 (78%)
patients receiving BEMP and for 14 (49%) of the receiv-
ing P. In the second cycle, another five (10%) responded
to BEMP and 11 (40%) to P. So, responses occurred
early in both arms. The median duration of response
among those who did respond was 9.2 months and 7.1
months for BEMP and P, respectively. For patients with
only lung and/or lymph node metastases and no loco-
regional disease the median duration of response was
11.5 months and 7.2 months for BEMP and P, respec-
tively, and for those with stage IVB disease it was 7.6
and 7.5 months, respectively.
Median progression-free survival and overall survival
figures with their 95% confidence intervals (CI) are given
in Table 5. There was neither a significant difference in
progression-free survival nor in overall survival between
the two arms of the study (Figures 2 and 3), although for
the first a trend in favor of BEMP existed.
In a prognostic factor analysis on all eligible patients
11 variables were included: treatment, age, performance
status, prior radiotherapy, prior surgery, extent of dis-
ease (i.e., only distant metastases or distant metastases
with locoregional involvement), the localisation of the
metastases (i.e., only lung and/or lymph node metas-
tases or also elsewhere), FIGO stage, initial WBC and
initial platelet count. The risk ratios of treatment did not
change when a correction was done for potential prog-
nostic factors. In a backward selection procedure on the
Cox model including all prognostic factors and treat-
ment the following variables were retained in the model
when the analysis was done for survival: age (P = 0.0003),
performance status (P = 0.0001), and interval since
diagnosis (P = 0.0152). Lower age, lower performance
status and an interval since diagnosis of less than one
year were all associated with an increased risk of dying.
In the analysis for progression-free survival, next to age
(P - 0.0031), prior radiotherapy (P - 0.0176), prior
surgery (P = 0.0099) and extent of disease (P = 0.0214)
were retained in the model. Lower age, prior radio-
Number of patients at risk
125 140
135 141
Treatment
- BEMP
Figure 2. Progression-free survival of all patients in the BEMP arm
and the P arm for whom survival data are available.
Number of patients at risk Trootmonl
• BEMP
5 P
Figure 3 Overall survival of all patients in the BEMP arm and the P
arm for whom survival data are available.
therapy, no prior surgery and locoregional involvement
were associated with a high risk.
Discussion
Our study showed that aggressive platinum-based
combination chemotherapy produced significantly more
toxicity and a higher response rate compared with cis-
platin alone in patients with disseminated SCCUC, but
this did not translate into survival benefit. In that sense
our study is in agreement with those of others, who
reported on direct comparisons between cisplatin alone
and combinations including cisplatin [17, 18]. In those
two other studies cisplatin dose was the same as in our
study, i.e. 50 mg/m2, both in the single-agent reference
arm and in the combination arms.
The Southwest Oncology Group reported on a
randomized phase II trial of a four-drug regimen VBMP
(vincristine, bleomycin, mitomycin-C, cisplatin), a two-
drug regimen MP, and cisplatin as a single agent.
Although that study was not designed as a phase III
comparison, the results suggested no significant differ-
ences in objective response rates to the three different
treatment [17]. The overall objective response rates for
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cisplatin, MP, and VBMP treated patients were 33%,
25%, and 22%, respectively. Also response duration or
survival duration seemed not between the three regimens.
Median survival durations associated with cisplatin, MP,
and VBMP treatment were 17.0, 7.0, and 6.9 months,
respectively. However, the comparison was hampered by
the fact that the third arm, cisplatin only, was dropped
early because of poor accrual (doctors bias), and the
study continued only into the two combination arms.
Severe or life threatening leukopenia and thrombocyto-
penia were observed in 18%—24% of patients treated
with VBMP and MP, but in none of those receiving
cisplatin alone.
The large Gynecologic Oncology Group phase III
study of cisplatin versus cisplatin plus mitolactol (dibro-
modulcitol) versus cisplatin plus ifosfamide was per-
formed in 454 patients, and again showed no improve-
ment in survival with these combinations [18]. Never-
theless, one of these combination regimens (cisplatin
plus ifosfamide) had a significantly higher response rate
(31.1% vs. 17.8%, P = 0.004) and progression-free sur-
vival (4.6 vs. 3.2 months, median; P = 0.003) compared
to cisplatin alone. This gain was obtained at the cost of
greater toxicity. Leukopenia, renal toxicity, peripheral
neurotoxicity and central nervous system toxicity were
significantly more frequent with cisplatin plus ifosfamide
(P < 0.05).
From that GOG study some promise was expected
from the addition of bleomycin to the cisplatin plus
ifosfamide combination, because of promising data
from this so-called BIP regimen in some phase II studies
[19, 20]. In those studies overall response rates varied
from 66.6% to 69% and complete response rates were
19% and 20%. In a comparative (but not randomized)
study of BIP versus cisplatin alone in a limited number
of patients (n = 106), performed by the same group of
investigators who reported on the promising phase II
data, BIP did not seem to improve survival, while it
induced two toxic deaths in the 56 patients who received
it [21]. Other investigators reported much less favorable
results with BIP and stressed the considerable toxicity
which it can induce [22]. Clearly the emphasis in future
studies should be placed on the development of more
active single agents and combinations or various novel
treatment approaches.
There are several new cytotoxic agents which seem
to be of interest for future studies, either alone or in
combination with existing active conventional agents.
These agents are the taxoids paclitaxel and docetaxel
[23-25], the topoisomerase I inhibitors irinotecan and
topotecan [26-31], the vinca-alkaloid vinorelbine [32-34]
and the antimetabolite gemcitabine [35, 36]. Combina-
tions of these newer agents with cisplatin in phase II
studies have resulted in response rates varying from 41%
to 67%, each with 95% confidence intervals, which are
overlapping with those obtained in earlier platinum-
based regimens not including these newer agents [37-41].
It is therefore questionable whether these newer combi-
nations will have any impact on the survival of patients
with recurrent or metastatic cervical cancer. Randomized
comparisons of such newer combination versus cisplatin
alone seem warranted. However, this is only defensible
when adequate numbers of patients are included in such
studies and preferably quality of life studies are inte-
grated. In the set up of such studies it is of importance
to take into account important factors which may have
impact on the chance to response to chemotherapy.
Whatever type of chemotherapy is used, results are influ-
enced by characteristics such as age and performance
status of the patient, the site of the disease involved
(pelvic or extrapelvic), the extent of the disease (distant
metastases only or together with locoregional disease),
the location of the metastases, and whether the lesions
are located in a previously irradiated area [1, 42]. From
the multivariate analysis performed in the GOG phase
III trial, comparing cisplatin plus mitolactol versus cis-
platin plus ifosfamide versus cisplatin alone a significant
association was found between survival duration and
initial performance status (PS of 0 was more favorable,
P < 0.001) and age (younger was unfavorable, P = 0.025).
The outcome of the multivariate analysis in our study
was completely in agreement with this: both a lower age
(P = 0.003) and a lower performance status (P = 0.0001)
were associated with an increased risk of dying. In
addition, a shorter interval since initial diagnosis seemed
to have a negative influence (P = 0.0152). Lower age,
prior therapy with radiotherapy or no prior surgery and
locoregional involvement all had a negative impact on
progression-free survival in our study.
Outside trials, the use of cisplatin alone is still the
gold standard if one decides to use chemotherapy for
palliation. The use of more aggressive regimens, which
all result in considerable toxicity remains questionable.
An individual approach to these patients is warranted,
whereby identification of a subset of patients who indeed
might benefit from chemotherapy is a major issue. Any
decision for treatment of cervical cancer patient in the
palliative setting should be assessed against the benefit
of best supportive care, which may provide the best
option for some of these patients.
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